Affiliation:
1. Department of Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Southeast
University, Nanjing 211189, PR China
2. Department of Medicinal Chemistry, School of Pharmacy, Nanjing
Medical University, Nanjing 211166, PR China
3. Southeast University Pharmaceutical Engineering Nanjing China
Abstract
Background::
Ischemic stroke, the most common type of cerebrovascular accident,
is a major cause of severe disability among adults worldwide. Although there has
been progress in interventions for ischemic stroke in the past decades, there is no effective
treatment to prevent brain damage in acute ischemic stroke. Therefore, it is urgent
to develop novel neuroprotective agents with a wide therapeutic time window to provide
a better prognosis for ischemic stroke patients.
Objective::
The current study aimed to synthesize novel derivatives with substituent cinnamide
scaffolds, evaluate biological activity, and obtain neuroprotective agents.
Methods::
The target compounds were synthesized using classical methods of medicinal
chemistry. The neuroprotective effects in vitro against Glu-induced neurotoxicity injury
were evaluated in PC12 cells by MTT assay. The cell apoptosis was analyzed by flow
cytometer. The proteins were detected by western blotting. The neuroprotective activities
in vivo were determined in two in vivo models of global and focal cerebral ischemia.
Results::
Among the title compounds, 9t, 9u, 9y, and 9z exhibited good neuroprotection
in vivo and in vitro, which were selected and further studied to determine their mechanism
of action. 9t, 9u, 9y and 9z protected PC12 cells against glutamate-induced apoptosis
in a dose-dependent manner via caspase-3 pathway. Moreover, the four compounds
significantly reduced brain infarct area and exhibited excellent neuroprotective activities
in the in vivo MCAO model.
Conclusion::
Compounds 9t, 9u, 9y, and 9z, as potent neuroprotective agents with anti-
neurotoxicity activity in vitro and anticerebral infarction efficacy in vivo, might serve
as a useful molecular tool for further physiology and pathophysiology function studies,
leading to potential clinical therapeutic agents for ischemic injury.
Publisher
Bentham Science Publishers Ltd.